These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19560836)

  • 1. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.
    Jeong SH; Jung JH; Han JH; Kim JH; Choi YW; Lee HW; Kang SY; Hwang YH; Ahn MS; Choi JH; Oh YT; Chun M; Kang S; Park KJ; Hwang SC; Sheen SS
    Lung Cancer; 2010 May; 68(2):288-94. PubMed ID: 19560836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer.
    Lee HW; Han JH; Kim JH; Lee MH; Jeong SH; Kang SY; Choi JH; Oh YT; Park KJ; Hwang SC; Sheen SS; Lim HY
    Lung Cancer; 2008 Jan; 59(1):95-104. PubMed ID: 17889401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.
    Lee HW; Choi YW; Han JH; Kim JH; Jung JH; Jeong SH; Kang SY; Choi JH; Oh YT; Park KJ; Hwang SC; Sheen SS
    Lung Cancer; 2009 Sep; 65(3):377-82. PubMed ID: 19150580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
    Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The addition of induction chemotherapy with etoposide, ifosfamide, and cisplatin failed to improve therapeutic outcome of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer -- single institution retrospective analysis.
    Lee HW; Choi JH; Lim HY; Park JS; Kim HC; Kang S; Oh YT; Chun M; Sheen SS; Oh YJ; Park KJ; Hwang SC
    Neoplasma; 2006; 53(1):30-6. PubMed ID: 16416010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
    Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy.
    Kang SY; Han JH; Lee KJ; Choi JH; Park JI; Kim HI; Lee HW; Jang JH; Park JS; Kim HC; Kang S; Oh YT; Chun M; Kim JH; Sheen SS; Lim HY
    Clin Cancer Res; 2007 Jul; 13(14):4146-53. PubMed ID: 17634542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
    Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy.
    Giatromanolaki A; Koukourakis M; Zaramboukas T; Skordalaki A; Arapantoni P; Georgoulias V; Fountzilas G
    Anticancer Res; 1998; 18(6B):4685-92. PubMed ID: 9891541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone.
    Huang EH; Liao Z; Cox JD; Guerrero TM; Chang JY; Jeter M; Borghero Y; Wei X; Fossella F; Herbst RS; Blumenschein GR; Moran C; Allen PK; Komaki R
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):779-85. PubMed ID: 17418967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
    Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
    Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
    Zatloukal P; Petruzelka L; Zemanova M; Havel L; Janku F; Judas L; Kubik A; Krepela E; Fiala P; Pecen L
    Lung Cancer; 2004 Oct; 46(1):87-98. PubMed ID: 15364136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis.
    Yaren A; Oztop I; Kargi A; Ulukus C; Onen A; Sanli A; Binicier O; Yilmaz U; Alakavuklar M
    Int J Clin Pract; 2006 Jun; 60(6):675-82. PubMed ID: 16805752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation.
    Langer CJ; Curran WJ; Keller SM; Catalano RB; Litwin S; Blankstein KB; Haas N; Campli SN; Comis RL
    Cancer J Sci Am; 1996; 2(2):99-105. PubMed ID: 9166507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does response to induction chemotherapy predict survival for locally advanced non-small-cell lung cancer? Secondary analysis of RTOG 8804/8808.
    McAleer MF; Moughan J; Byhardt RW; Cox JD; Sause WT; Komaki R
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):802-8. PubMed ID: 19540055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.